Over 156,000 adults in Europe are hospitalised each year due to RSV, a virus that can cause severe lung issues.

AstraZeneca and Sino Biopharmaceutical's subsidiary CTTQ have signed an exclusive licence agreement for TQC3721.

Evogene and Tel Aviv University’s BCDD have partnered to expedite small-molecule drug discovery originating from Israeli academic research.

The FDA is taking action to curb the illicit online trade of unregulated and unapproved ketamine products through a slew of warning letters.

The US FDA has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for CMT2S.

The biotech’s potential launch on the public markets would help fuel development of its clinical-stage, melanocortin-focused pipeline.

Novo Nordisk has taken an interest in a weight-loss implant developed by Californian medtech Vivani Medical, reflecting a broadening of the drugmaker’s strategy to fend off mark ...

Biocytogen and Whitehawk Therapeutics are set to develop bispecific antibody-drug conjugates (BsADCs), as part of a global partnership.

The EC has granted marketing authorisation for AbbVie’s Tepkinly in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.

Servier’s head of business development Frederic Scaerou discusses the French company’s recent string of dealmaking.

Through predictive modelling, AI supports target identification, prediction of physicochemical properties and formulation strategy selection.

Fresh with a rebrand, Cyllene will advance gene therapies built on a platform that uses a modified form of the herpes virus for delivery.